Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts AMPH Hot Sheet
Price: $25.14 -3.46%
Rating Summary:
2 Buy, 8 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
2 Buy, 8 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Jefferies raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $19.00) while maintaining a Buy rating.
Analyst David Steinberg notes revenue for the quarter came in slightly above their estimates at $57.9M largely due to better than expected Naloxone revs. The EPS beat was partially due to lower R&D spend.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zymeworks (ZYME) PT Raised to $52 at Jefferies
- Civista Bancshares (CIVB) PT Raised to $33 at DA Davidson
- Lockheed Martin (LMT) PT Raised to $692 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
